Skip to main content

Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy

Buy Article:

$113.00 plus tax (Refund Policy)

Abstract:

The IGF system plays a major role in growth, development and maintenance of homeostasis in normal cells and also contributes towards proliferation of malignant cells. Any disruption in the IGF system has its implications on growth retardation, atherosclerosis, insulin resistance and cancer. Imbalances in the IGF axis are known to contribute towards the progression of breast cancer. Due to the ubiquitous nature of the components of the IGF system, targeting specific members of the axis has gained attention over the past decades. The most elaborately investigated component as a therapeutic target in the system is the IGF-IR and studies have been pursued to inhibit IGF-IR by the administration of monoclonal antibodies and tyrosine kinase inhibitors. Very recently, a novel cell death receptor that binds specifically to IGFBP-3 was identified. It has also been shown that the IGFBP-3/IGFBP-3 receptor may be impaired in breast and prostate cancer. In this review, we present the mechanisms used to target the IGF system in various diseased states, emphasizing on breast cancer. We further discuss currently available therapeutic approaches and summarize the latest patents published in the field of IGF-I/IGF-IR and IGFBP-3/IGFBP-3R systems.





Keywords: Anti-cancer drugs; ENDOCRINE DISORDERS; IGF system; IGF-IR; IGFBP-3; IGFBP-3R; breast cancer; cancer therapy; homeostasis; patents; tyrosine kinase inhibitors

Document Type: Research Article

DOI: https://doi.org/10.2174/157489211795328512

Publication date: 2011-05-01

More about this publication?
  • Recent Patents on Anti-Cancer Drug Discovery publishes review articles on recent patents in the field of anti-cancer drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more